A Study to Test the Safety of Three Experimental HIV Vaccines

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

There are currently several Phase I and II clinical trials being performed within AVEG to evaluate different HIV-1 vaccine candidates. The HIV-1 vaccination approach that is furthest along the clinical development pathway is the so-called prime-boost regimen of live recombinant canarypox priming (ALVAC-HIV vCP205) with recombinant subunit protein boosting (HIV-1 SF-2 rgp120 in MF59 adjuvant). The protein boost enhances neutralizing antibody responses against laboratory strains of HIV-1 in assays performed in vitro, as well as enhancing CD4 cell response and increasing the frequency of CD8 c...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• You may be eligible for this study if you:
• • Are between the ages of 18 and 60.
• • Are HIV-negative.
• • Are negative for Hepatitis B.
• • Have a normal physical exam.
• • Are available for 18 months of follow-up.
• • Agree to use an effective method of birth control for 1 month before receiving a vaccine and during the study.
• • Exclusion Criteria
• You will not be eligible for this study if you:
• • Have a history of an immunodeficiency, chronic illness, or cancer.
• • Have a medical or psychiatric condition which would make you unable to comply with the study.
• • Are at higher-risk for HIV infection; for example, have a history of injection drug use in the past year or practice higher risk sexual behavior.
• • Have syphilis or tuberculosis.
• • Have received a live vaccine in the past 60 days, have ever received an HIV vaccine or placebo in a previous HIV vaccine study, or have ever received a rabies vaccine.
• • Have a history of a serious allergic reaction to a vaccine or to any other substance, including neomycin or egg products.
• • Have received certain medications.
• • Are pregnant or breast-feeding.

Trial Officials